Skip Navigation

  1. Acerca de Nosotros
    1. Visión General
    2. Historia
    3. Oficinas
  2. Nuestra Experiencia
    1. Áreas de Trabajo
      1. Patentes
      2. Marcas
      3. Derecho de Autor
      4. Derecho Corporativo y Mercantil
      5. Litigio de Propiedad Intelectual y Resolución Alternativa de Disputas
      6. Práctica Regulatoria
      7. Otorgamiento de Licencias, Transferencia de Tecnología y Franquicias
      8. Anti-Piratería, Anti-Falsificación & Aplicación
    2. Grupos de la Industria
      1. Grupo de Abogados en Medios, Deportes y Entretenimiento
      2. Grupo de Abogados e Ingenieros en Ciencias de la Vida
  3. Nuestra Gente
    1. Socios
      1. Sergio L. Olivares, Sr. † (1931-2010)
      2. Sergio L. Olivares, Jr.
      3. Luis C. Schmidt
      4. César Ramos, Jr.
      5. Antonio Belaunzarán
      6. Gustavo A. Alcocer
      7. José Ignacio de Santiago
      8. Alejandro Luna
      9. Alonso Camargo
      10. Daniel Sánchez
    2. Asociados (A - M)
      1. Osvaldo Amaral
      2. Armando Arenas
      3. Sofía Arroyo
      4. Guillermo Ballesteros
      5. Varinia Calleros
      6. Abraham Diaz
      7. Georgina Flores
      8. Pedro Herrera
      9. Carlos Maya
    3. Asociados (N - Z)
      1. Mauricio Narváez
      2. Víctor Ramírez
      3. Sergio Rangel
      4. Maria del Carmen Sada
      5. Juan Luis Serrano
      6. Guillermo Treviño
      7. Carlos Woodworth
    4. Abogados / Ingenieros
    5. Administración de la firma
  4. Conocimiento & Recursos
    1. Artículos y Estudios de Casos
      1. Artículos sobre Marcas
        1. Use requirements
        2. Approach to composite marks changed, again
        3. Life Sciences Handbook 2011 - Country Q&A
        4. Mexico should accept secondary meaning
        5. Getting the Deal Through - Trademarks 2011
        6. Pharmaceutical Trademarks 2010/2011 - A Global Guide
        7. No legal basis for banning names derived from INNs
        8. How Latin America tackles cutting-edge IP issues
        9. Specialised IP court corrects IMPI
        10. Protecting trade dress
        11. 43 more items...
      2. Artículos sobre Patentes
        1. Mexican Linkage Gazette April 2011
        2. Mexico issues regulations to approve biologic drugs
        3. Latin America Roundtable
        4. New regulations pending
        5. The International Comparative Guide
        6. Marketing authorization for pharmaceutical
        7. Approval of follow-on biologics in Mexico
        8. Patent Prosecution Highway in Mexico
        9. Life Sciences Handbook 2011 - Country Q&A
        10. Data Package Exclusivity (DPE)
        11. 35 more items...
      3. Artículos sobre Derecho de Autor
        1. Publicidad en redes sociales
        2. Technology challenges digital rights
        3. Exceptions to copyright protection and the permitted uses of copyright works in the hi-tech and digital sectors
        4. Derechos sobre producción audiovisual
        5. How Latin America tackles cutting-edge IP issues
        6. Copyright Litigation 2010
        7. Legislation and enforcement - Copyrights 2010
        8. Valuing folklore
        9. Protecting novel ideas
        10. Mexico's fair use balancing act
        11. 97 more items...
      4. Artículos sobre Derecho Corporativo
        1. Mexico issues Personal Data Protection Rules
        2. A practical cross-border
        3. New registry for security interests
        4. The International Comparative Legal Guide to: Merger Control 2011
        5. The International Comparative Legal Guide to: Merger Control 2010
        6. Due diligence issues to consider in M&A
        7. Income expectations in licensing
        8. The reasons for valuation
        9. Amendments proposed to franchise regulation
      5. Artículos sobre Litigio y RAD
        1. Scope of new specialised courts widened
        2. Reform of preliminary injunctions
        3. Mexican Patent Office excludes Formulation Patents from Linkage Gazette
        4. Mexico gets ready to approve biocomparable drugs
        5. Mexico's hotel for the stars highlights power in the name
        6. Supreme Court upholds the worth of formulation patents
        7. Getting the Deal Through - Patents 2010
        8. Getting the Deal Through Trademarks 2010
        9. Trademark enforcement
        10. Venues for appealing IMPI decisions
        11. 15 more items...
      6. Artículos sobre Derecho Regulatorio
        1. Recientes enmiendas a la Ley Federal de Protección al Consumidor
        2. Enmiendas en la Ley Federal de Protección al Consumidor
        3. Mexico issues Personal Data Protection Rules
        4. New Regulations Pending
        5. Marketing authorization for pharmaceutical products to foreign applicants
        6. Data Package Exclusivity (DPE)
        7. Supreme Court upholds the worth of formulation patents
        8. Pharmaceutical trademarks
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Advertising 2009
        11. 4 more items...
      7. Artículos sobre Licencias y Transferencia de Tecnología
        1. Creating a secure franchise system
      8. Artículos sobre Anti-piratería y Anti-falsificación
        1. New register against counterfeits
        2. Beat the counterfeiters in Mexico
        3. Battling counterfeits through Customs
        4. Getting the Deal Through Trademarks 2010
        5. Enforcing plant variety rights in Mexico
        6. Pharmaceutical Trademarks 2009
        7. Internet Issues
        8. Anti-counterfeiting 2009
        9. Vegetal variety rights enforced
        10. New Customs rules lead to seizures
        11. 4 more items...
      9. Artículos en relación con Medios, Deportes y Entretenimiento
        1. Publicidad en redes sociales
        2. Whither Rental Rights?
        3. Improved protection for personalities
      10. Artículos en relación con Ciencias de la Vida
        1. Latin America Roundtable
        2. New regulations pending
        3. The International Comparative
        4. Approval of follow-on biologics in Mexico
        5. Global Pharmaceutical Linkage Regulations:
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Supreme Court upholds the worth of formulation patents
        8. Repercussions expected on medicine advertising campaign in Mexico
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Trademarks 2009
        11. 1 more item...
  5. Oficinas
  6. Eventos
  7. Contacto

Español » Conocimiento & Recursos » Artículos y Estudios de Casos » Artículos sobre Marcas » No legal basis for banning names derived from INNs

No legal basis for banning names derived from INNs

por Varinia Calleros
International Briefings, Managing Intellectual Property, November 2010
International Non-Proprietary Names (INNs) are names for pharmaceutical substances or active pharmaceutical ingredients recognised as public property. They are treated as generic names by international authorities, with around 8,000 published at present.
The World Health Organisation (WHO) provides guidelines for its member states, of which Mexico is one, on the use of INNs – particularly to prevent registration of INNs and names derived from them that comprise INN prefixes or suffixes (so-called stems).
It is common practice for pharmaceutical companies to include INNs or stems as part of their trade marks, which creates conflicting situations for the Mexican Trademark Office.
On the one hand, only registration of generic names is prohibited under Section II of article 90 of the Mexican Industrial Property Law, which establishes that the following cannot be registered as trade marks: “II: The technical names or common usage of the products or services the trade mark intends to cover as well as words that, in the common language or commercial practice, have been converted into the usual or generic designation of the same.”
Accordingly, the Office has no legal basis to refuse a trade mark that comprises a stem or INN as long as it includes additional distinctive elements that make the trade mark registrable as a whole.
On the other hand, INNs are generic and cannot be treated otherwise, which makes it impossible for the TMO to assess the likelihood of confusion between pharmaceutical trade marks and INNs.
So it is hard for the Office to follow the WHO’s recommendations to safeguard the proper use of INNs and avoid registration of trademarks derived from them without an amendment to article 90 of the Law.